20 March 2017

Posting of Annual report & Notice of AGM

RNS Number : 9721Z

Read more

2 March 2017

PDMR Dealing

RNS Number : 3484Y

Read more

2 March 2017

PDMR Dealing

RNS Number : 3484Y

Read more

27 February 2017

Final Results

RNS Number : 8595X

Read more

27 February 2017

Final Results

RNS Number : 8595X

Read more

23 February 2017

Notice of Results

RNS Number : 6404X Verona Pharma PLC 23 February 2017

Read more

23 February 2017

Notice of Results

RNS Number : 6404X

Read more

22 February 2017

First COPD patient dosed with RPL554

RNS Number : 4893X Verona Pharma PLC 22 February 2017

Read more

13 February 2017

Total Voting Rights & Block Listing Interim Review

RNS Number : 6715W Verona Pharma PLC 13 February 2017

Read more

8 February 2017

Result of General Meeting and Share Consolidation

RNS Number : 3641W Verona Pharma PLC 08 February 2017

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us